Page 191 – The development of a new service for patients with hyperlipidaemia and ischaemic heart disease in Cwm Taf University Health Board
Dr David Cassidy
References
- NICE. Cardiovascular disease risk assessment and reduction including lipid modification. CG 181 2014. Available at: https://www.nice.org.uk/guidance/cg181
- NICE. Alirocumab for treating hypercholesterolaemia and mixed dyslipidaemia. Technical appraisal guidance 393 2016. Available at: https://www.nice.org.uk/guidance/ta393
- NICE. Evolocumab for treating hypercholesterolaemia and mixed dyslipidaemia. Technical appraisal guidance 394 2016. Available at: https://www.nice.org.uk/guidance/ta394